According to Fortune Business Insights, the global hereditary angioedema treatment market size was valued at USD 5.59 billion in 2024 and is projected to grow from USD 6.53 billion in 2025 to USD 19.68 billion by 2032, exhibiting a CAGR of 17.1% during the forecast period (2025–2032). North America dominated the market with a share of 93.05% in 2024.
